Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncologicas (CNIO), Molecular Cytogenetics & Genome Editing Unit, Melchor Fernandez Almagro, 3, 28029 Madrid, Spain.
Centro de Investigacion Energeticas Medioambientales y Tecnologicas (CIEMAT), Advanced Therapies Unit, Hematopoietic Innovative Therapies Division, Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS-FJD, UAM), 28040 Madrid, Spain.
Int J Mol Sci. 2022 Feb 3;23(3):1757. doi: 10.3390/ijms23031757.
CRISPR/Cas is a prokaryotic self-defense system, widely known for its use as a gene-editing tool. Because of their high specificity to detect DNA and RNA sequences, different CRISPR systems have been adapted for nucleic acid detection. CRISPR detection technologies differ highly among them, since they are based on four of the six major subtypes of CRISPR systems. In just 5 years, the CRISPR diagnostic field has rapidly expanded, growing from a set of specific molecular biology discoveries to multiple FDA-authorized COVID-19 tests and the establishment of several companies. CRISPR-based detection methods are coupled with pre-existing preamplification and readout technologies, achieving sensitivity and reproducibility comparable to the current gold standard nucleic acid detection methods. Moreover, they are very versatile, can be easily implemented to detect emerging pathogens and new clinically relevant mutations, and offer multiplexing capability. The advantages of the CRISPR-based diagnostic approaches are a short sample-to-answer time and no requirement of laboratory settings; they are also much more affordable than current nucleic acid detection procedures. In this review, we summarize the applications and development trends of the CRISPR/Cas13 system in the identification of particular pathogens and mutations and discuss the challenges and future prospects of CRISPR-based diagnostic platforms in biomedicine.
CRISPR/Cas 是一种原核生物的自我防御系统,因其作为基因编辑工具而广为人知。由于其对 DNA 和 RNA 序列具有高度特异性的检测能力,不同的 CRISPR 系统已被用于核酸检测。CRISPR 检测技术之间存在很大差异,因为它们基于 CRISPR 系统的六个主要亚型中的四个。在短短 5 年内,CRISPR 诊断领域迅速发展,从一系列特定的分子生物学发现发展到多个获得 FDA 批准的 COVID-19 检测以及几家公司的建立。基于 CRISPR 的检测方法与现有的预扩增和读出技术相结合,实现了与当前金标准核酸检测方法相当的灵敏度和重现性。此外,它们非常多功能,可以轻松实现对新兴病原体和新的临床相关突变的检测,并提供多重检测能力。基于 CRISPR 的诊断方法的优点是样本到答案的时间短,且无需实验室设置;它们也比当前的核酸检测程序便宜得多。在这篇综述中,我们总结了 CRISPR/Cas13 系统在特定病原体和突变识别中的应用和发展趋势,并讨论了基于 CRISPR 的诊断平台在生物医学中的挑战和未来前景。